By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GeneNews announced after the close of the market on Wednesday a rights offering intended to raise about C$2.5 million (US$2.6 million).

Proceeds from the offering will go toward commercialization of the Toronto-based molecular diagnostics firm's ColonSentry test, a blood-based colon cancer risk stratification test, and for general corporate and administrative expenses, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.